Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Eterna Therapeutics (ERNA)
NASDAQ:ERNA
RESEARCH TOOLSreports
Holding ERNA?
Track your performance easily
ERNA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.84 - $2.63
Previous Close$1.85
Volume2.05K
Average Volume (3M)7.72K
Market Cap
$10.01M
Enterprise Value$56.61M
Total Cash (Recent Filing)$2.60M
Total Debt (Recent Filing)$49.20M
Price to Earnings (P/E)―
Beta0.97
Next Earnings
Apr 14, 2023EPS Estimate
-$2.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.42
Shares Outstanding5,410,588
10 Day Avg. Volume3,276
30 Day Avg. Volume7,716
Standard Deviation1.64
R-Squared0.02
Alpha0.09
Financial Highlights & Ratios
Price to Book (P/B)-0.96
Price to Sales (P/S)62.12
Price to Cash Flow (P/CF)-1.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue401.52
Enterprise Value/Gross Profit-336.99
Enterprise Value/Ebitda-2.90
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Eterna Therapeutics News
PremiumPress Releases
Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs in Inflammatory Diseases
PremiumCompany Announcements
Eterna Therapeutics Welcomes New Board Member Peter CicalaRisk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ERNA FAQ
What was Eterna Therapeutics’s price range in the past 12 months?
Eterna Therapeutics lowest stock price was $0.84 and its highest was $2.63 in the past 12 months.
What is Eterna Therapeutics’s market cap?
Currently, no data Available
When is Eterna Therapeutics’s upcoming earnings report date?
Eterna Therapeutics’s upcoming earnings report date is Apr 14, 2023 which is 498 days ago.
How were Eterna Therapeutics’s earnings last quarter?
Eterna Therapeutics released its earnings results on Nov 08, 2022. The company reported -$2.488 earnings per share for the quarter, missing the consensus estimate of -$2.2 by -$0.288.
Is Eterna Therapeutics overvalued?
According to Wall Street analysts Eterna Therapeutics’s price is currently Overvalued.
Does Eterna Therapeutics pay dividends?
Eterna Therapeutics does not currently pay dividends.
What is Eterna Therapeutics’s EPS estimate?
Eterna Therapeutics’s EPS estimate is -$2.4.
How many shares outstanding does Eterna Therapeutics have?
Eterna Therapeutics has 5,410,588 shares outstanding.
What happened to Eterna Therapeutics’s price movement after its last earnings report?
Eterna Therapeutics reported an EPS of -$2.488 in its last earnings report, missing expectations of -$2.2. Following the earnings report the stock price went up 3.67%.
Which hedge fund is a major shareholder of Eterna Therapeutics?
Currently, no hedge funds are holding shares in ERNA
---
Eterna Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-19.56%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-1.00%
Trailing 12-Months
Company Description
Eterna Therapeutics
NTN Buzztime, Inc. engages in the provision of entertainment and innovative technology services. It offers entertainment, live events, dining, marketing, hardware, and pricing products. It also includes performance analytics and secure payment with Europay, MasterCard, and Visa chip readers or with near-field communication (NFC) technology to accept Apple, Android, and Samsung Pay. The company was founded in 1984 and is headquartered in Carlsbad, CA.
---
Technical Analysis
Abeona Therapeutics
―
Apellis Pharmaceuticals
―
Arcturus Therapeutics
―
Arvinas Holding Company
―
---